ONWARD Medical's Capital Increase Announcement
ONWARD Medical N.V. (OTC: ONWRY), a pioneering leader in neurotechnology, has announced an exciting capital increase strategy. The company aims to raise approximately EUR 50 million through a private placement, designed to strengthen its efforts in developing innovative therapies that restore movement and independence to individuals with spinal cord injuries.
Details of the Offering
The capital increase will be initiated via a bookbuild offering to institutional investors. This provides an opportunity for both existing and new shareholders to invest in ONWARD Medical. The company plans to offer ordinary shares at a nominal value of EUR 0.12 each, with the final number of New Shares and their pricing to be disclosed following the completion of the bookbuilding process.
Use of Proceeds
ONWARD Medical has outlined a strategic plan for the utilization of the proceeds from this capital increase. The funds will primarily be allocated to:
- Support the development of their investigational ARC-IM System, aimed at improving blood pressure stability in individuals with spinal cord injuries, which will consume about 40% of the funds.
- Expand sales operations for the ARC-EX System across various markets, constituting 30% of the budget.
- Scale quality control and administrative activities to ensure optimal operational efficiency, utilizing 20% of the funds.
- Allocate 5% for working capital and other general corporate purposes.
- Set aside another 5% to cover financing costs, including existing debt obligations.
Market Participation and Trading Suspension
In an effort to ensure broader participation, trading of ONWARD Medical's shares will be temporarily halted during the bookbuilding period to allow for a more extensive inclusion of institutional investors. This decision is made in accordance with guidance from Euronext, emphasizing ONWARD's commitment to maximizing investor participation.
Private Placement Logistics
The bookbuilding is set to commence immediately with an intended duration of one business day, although this may be adjusted for broader inclusion. The company anticipates closing trading temporarily to facilitate this process and will provide updates on the number of shares and issue price once available.
Company Overview: ONWARD Medical
Headquartered in the Netherlands, ONWARD Medical is focused on developing and applying groundbreaking neurotechnology to aid individuals with spinal cord injuries. Their innovative therapies, especially the ARC Therapy, have received multiple endorsements, including ten Breakthrough Device Designations from the FDA.
Among their key products is the ARC-EX System, which is already commercially available in the US and Europe. The company is actively working on the ARC-IM System, an investigational device targeting critical issues faced by patients post-spinal cord injury. This device aims to leverage artificial intelligence to help restore movement through advanced neural interfacing.
The Future of ONWARD Medical
With this capital increase, ONWARD Medical is not just enhancing its financial stability but also paving the way for groundbreaking advancements in treatment options for spinal cord injuries. The funds are set to extend the company's cash runway through at least the end of 2026, ensuring continued progress in critical development initiatives.
As the company forges ahead with these plans, it emphasizes its dedication to improving the lives of those with mobility impairments through innovative therapies.
Frequently Asked Questions
What is the purpose of ONWARD Medical's capital increase?
The capital increase aims to raise EUR 50 million to support ongoing therapy development projects and expand sales operations of their products.
What specific products will benefit from the new funding?
The ARC-IM System and ARC-EX System will be the primary areas of focus for the allocation of funds from this capital increase.
How will the capital increase impact investors?
The capital increase offers existing and potential investors an opportunity to participate in the company's growth initiatives and future revenues.
Will trading of shares be affected during the offering period?
Yes, trading of ONWARD Medical shares will be temporarily halted to facilitate broader participation in the private placement.
Where can I find more information about ONWARD Medical?
More details about their products and clinical advancements can be found on ONWARD Medical’s official website.
